MediWound Ltd. (MDWD) Rating Lowered to Hold at Zacks Investment Research
MediWound Ltd. (NASDAQ:MDWD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
MDWD has been the topic of several other research reports. ValuEngine raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Friday, October 20th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $10.00 target price on shares of MediWound in a research note on Monday, September 18th. SunTrust Banks, Inc. set a $9.00 target price on shares of MediWound and gave the company a “buy” rating in a research note on Thursday, November 16th. Cowen and Company assumed coverage on shares of MediWound in a research note on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and set a $10.00 target price on shares of MediWound in a research note on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.13.
Shares of MediWound (MDWD) opened at $5.10 on Tuesday. MediWound has a 52-week low of $4.15 and a 52-week high of $8.25.
ILLEGAL ACTIVITY WARNING: “MediWound Ltd. (MDWD) Rating Lowered to Hold at Zacks Investment Research” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/23/mediwound-ltd-mdwd-rating-lowered-to-hold-at-zacks-investment-research.html.
A number of institutional investors have recently added to or reduced their stakes in the business. Migdal Insurance & Financial Holdings Ltd. increased its stake in MediWound by 9.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after buying an additional 192,860 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of MediWound in the 3rd quarter worth approximately $2,140,000. Nationwide Fund Advisors acquired a new position in shares of MediWound in the 3rd quarter worth approximately $1,538,000. Renaissance Technologies LLC grew its stake in shares of MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of MediWound by 23.5% in the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after purchasing an additional 12,522 shares during the last quarter. 27.12% of the stock is currently owned by hedge funds and other institutional investors.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.